跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

SML0036

Sigma-Aldrich

Procarbazine hydrochloride

≥98% (HPLC)

别名:

N-(1-Methylethyl)-4-[(2-methylhydrazinyl)methyl]benzamide hydrochloride

登录查看公司和协议定价

选择尺寸

10 MG
$86.70
50 MG
$349.00

$86.70

请联系客服了解存货情况
获取大包装报价
所有图片(1)

选择尺寸

变更视图
10 MG
$86.70
50 MG
$349.00

About This Item

经验公式（希尔记法）:
C12H19N3O·HCl
CAS号:
366-70-1
分子量:
257.76
EC 号:
206-678-6
MDL编号:
MFCD00072082
UNSPSC代码:
12352200
PubChem化学物质编号:
329825106
NACRES:
NA.77

$86.70

请联系客服了解存货情况
获取大包装报价

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to tan

溶解性

DMSO: ≥18 mg/mL

储存温度

2-8°C

SMILES字符串

Cl.CNNCc1ccc(cc1)C(=O)NC(C)C

InChI

1S/C12H19N3O.ClH/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3;/h4-7,9,13-14H,8H2,1-3H3,(H,15,16);1H

InChI key

DERJYEZSLHIUKF-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

应用

Procarbazine hydrochloride has been used to study its physicochemical property.[1]
Procarbazine, an antineoplastic alkylating agent, may be used to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an anticancer agent. It may be used to study new combination of anticancer drugs.

生化/生理作用

Procarbazine hydrochloride is a Antineoplastic alkylating agent
Procarbazine is an antineoplastic alkylating agent widely used in cancer chemotherapy in combination with other compounds. It has multiple mechanisms of action. Procarbazine inhibits protein, RNA and DNA synthesis in addition to being an alkylating agent.
Procarbazine is metabolized to azoprocarbazine either by cytochrome P450 enzyme and monoamine oxidase in an NADPH (nicotinamide adenine diphosphate) dependent or independent manner. It is considered neurotoxic.[2] Procarbazine is used in combination with therapy for treating Hodgkin′s disease.[3]

象形图

Health hazardExclamation mark
GHS08,GHS07

警示用语：

Danger

危险分类

Acute Tox. 4 Oral - Carc. 1B - Muta. 2 - Repr. 1A

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
065M4741V
022M4745V
051M4739V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Anti-Cancer Drug Design, 143-143 (1994)
Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies.
Michaela Rancea et al.
Journal of the National Cancer Institute, 104(14), NP-NP (2012-07-25)
eIF2alpha phosphorylation is pathognomonic for immunogenic cell death
Bezu L, et al.
Cell Death and Differentiation, 1-1 (2018)
Mary R Welch et al.
Neuro-oncology, 14(10), 1304-1311 (2012-09-07)
Up to 20% of all primary CNS lymphoma (PCNLS) patients are aged 80 years or older, yet data are limited on how best to treat this rapidly growing population. Despite demographic pressures and the proven efficacy of methotrexate (MTX)-based regimens
Marcus Hentrich et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(33), 4117-4123 (2012-10-10)
Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral therapy, standard therapy is still poorly defined. This prospective study investigates a stage- and risk-adapted treatment strategy in patients with HIV-HL.
查看所有相关文献

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门